ArticleCancer research and treatment2022
First Course of treatment and Prognosis of Exocrine Pancreatic Cancer in Korea from 2006 to 2017.
Article in Cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Long-term conditional relative survival trends in extrahepatic bile duct cancer: insights from a population-based retrospective cohort study in a high-incidence Asian Country, 1999-2021.International journal of surgery (London, England) · 2026Article
- Epidemiology of Gastric Cancer in Korea (1999-2022): Incidence, Survival, and 5-Year Conditional Relative Survival.Journal of gastric cancer · 2026Article
- Updates on incidence, mortality and survival of liver cancer using Korea central cancer registry database: 1999-2022.Annals of hepato-biliary-pancreatic surgery · 2025Article
- Incidence, mortality, and survival of gallbladder, extrahepatic bile duct, and pancreatic cancers in Korea: A population-based study from 1999 to 2022.Annals of hepato-biliary-pancreatic surgery · 2025Article
- Conditional Relative Survival of Exocrine Pancreatic Cancer: A Population-Based Study.Annals of surgical oncology · 2024Article
- Three-year follow-up study reveals improved survival rate in NSCLC patients underwent guideline-concordant diagnosis and treatment.Frontiers in oncology · 2024Article
- Exocrine pancreatic cancer as a second primary malignancy: A population-based study.Annals of hepato-biliary-pancreatic surgery · 2023Article
- Surgical management for elderly patients with pancreatic cancer.Annals of surgical treatment and research · 2023Review
- Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999-2019.Annals of hepato-biliary-pancreatic surgery · 2022Article
- Incidence, mortality and survival of gallbladder, extrahepatic bile duct, and pancreatic cancer using Korea central cancer registry database: 1999-2019.Annals of hepato-biliary-pancreatic surgery · 2022Article
- Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea.Journal of Korean medical science · 2022Article
- Epidemiology of Gastric Cancer in Korea: Trends in Incidence and Survival Based on Korea Central Cancer Registry Data (1999-2019).Journal of gastric cancer · 2022Review
- Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
purposeHospital-based clinical studies have limitations in holistic assessment of cancer treatment and prognosis, as they omit out-of-hospital patients including elderly individuals. This study aimed to investigate trends in initial treatment and corresponding prognosis of patients with exocrine pancreatic cancer (EPC) in Korea. MATERIALS AND
methodsThe Korea Central Cancer Registry data of patients with EPC from 2006 to 2017 were retrospectively reviewed. We defined the first course of treatment (FT) as the cancer-directed treatment administered within four months after cancer diagnosis according to the Surveillance, Epidemiology, and End Results (SEER) program.
resultsAmong 62,209 patients with EPC, localized and regional (LR) SEER stage; patients over 70 years old; and ductal adenocarcinoma excluding cystic or mucinous (DAC) accounted for 40.6%, 50.1%, and 95.9%, respectively. "No active treatment" (NT, 46.5%) was the most frequent, followed by non-surgical FT (28.7%) and surgical FT (22.0%). Among 25,198 patients with LR EPC, surgical FT increased (35.9% to 46.3%) and NT decreased (45.0% to 29.5%) from 2006 to 2017. The rate of surgical FT was inversely related to age (55.1% [< 70 years], 37.3% [70-79 years], 10.9% [≥ 80 years]). Five-year relative survival rates of LR DAC were higher after surgical FT than after NT in localized (46.1% vs. 12.9%) and regional stage (23.6% vs. 4.9%) from 2012 to 2017.
conclusionLess than half of overall patients with LR EPC underwent surgical FT, and this proportion decreased significantly in elderly individuals. Clinicians should focus attention on elderly patients with EPC to provide appropriate medical advice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.